每经记者:陈星 许立波每经编辑:张海妮图片来源:每日经济新闻(资料图)新药开发失败本是医药领域的常事,但诺和诺德近期却因一款肾病新药的开发失败向药物转让方索赔8.3亿美元。诺和诺德方面称,药物转让方KBP Biosciences(以下简称KBP)及创始人黄振华涉嫌故意未披露该药物试验中的重大不利信息,同时涉嫌存在资产转移的现实风险。而该药物转让方KBP及其创始人黄振华近期在官网发表声明回应:...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.